Capital Markets Day: Commercial Execution and Innovation in Obesity Care

14 Commercial execution and innovation Obesity care WegovyⓇ has reached more than 70% commercial formulary access within six months of launch WegovyⓇ Patient Access Pathway Obesity prevalence in adults People with obesity¹ ~100 M Commercially covered ~60 M WegovyⓇ formulary access >40 M Estimated WegovyⓇ employer opt-ins ~20 M ~125k Improving patient access remains the focus ~20 million people today with WegovyⓇ commercial coverage at the employer level . Formulary access (>70%) secured with all national PBMS • Access parity to Saxenda® achieved by 1 Jan 2022 PBMs recognising obesity as a disease and developing innovative programmes . ESI Weight Management Care Value™ Program CVS Health Nutrition & Coaching Services Program Expanding support for AOM coverage Novo NordiskⓇ . New coalition, KOL and stakeholder engagements • Broader engagement among policymakers at state and federal level Note: Obesity is defined as BMI > 30. people on WegovyⓇ today 1 Prevalence: Adult obesity facts. Centers for Disease Control and Prevention. Accessed Mar 2021. https://www.cdc.gov/obesity/data/adult.html; US Census Bureau. Quick Facts: United States. Accessed Mar, 2021. https://www.census.gov/quickfacts/fact/table/US#viewtop. PBM: Pharmacy benefit manager; AOM: Anti-obesity medication; KOLs: Key opinion leaders

View entire presentation